×
VivoSim Labs Other Non-Cash Items 2011-2025 | VIVS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
VivoSim Labs other non-cash items from 2011 to 2025. Other non-cash items can be defined as miscellaneous non-cash adjustments to Net income.
View More
VivoSim Labs Other Non-Cash Items 2011-2025 | VIVS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
VivoSim Labs other non-cash items from 2011 to 2025. Other non-cash items can be defined as miscellaneous non-cash adjustments to Net income.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$248.3B
Amgen (AMGN)
$155.9B
Gilead Sciences (GILD)
$142.4B
Vertex Pharmaceuticals (VRTX)
$99.3B
Bristol Myers Squibb (BMY)
$96.1B
GSK (GSK)
$81.1B
CSL (CSLLY)
$67.7B
Regeneron Pharmaceuticals (REGN)
$62.3B
Alnylam Pharmaceuticals (ALNY)
$59.1B
Argenex SE (ARGX)
$43.3B
Insmed (INSM)
$27.9B
BioNTech SE (BNTX)
$25.2B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$20B
Incyte (INCY)
$16.4B
Genmab (GNMSF)
$16B
Genmab (GMAB)
$15.7B
Illumina (ILMN)
$15.2B
Ascendis Pharma (ASND)
$12B
BioMarin Pharmaceutical (BMRN)
$11B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
QIAGEN (QGEN)
$10.9B
Exelixis (EXEL)
$10.3B
Moderna (MRNA)
$9.6B
Verona Pharma American Depositary Share (VRNA)
$9.1B
Bio-Techne Corp (TECH)
$8.9B
Exact Sciences (EXAS)
$8.7B
Halozyme Therapeutics (HALO)
$8.5B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8.1B